Recursion Pharmaceuticals is laying off a fifth of its workforce in connect with a previously announced streamlining of the AI biotech’s pipeline.

Long-term support release due in September brings features ranging from stable values and structured concurrency to ahead-of-time method profiling and JFR CPU-time profiling on Linux.

Chart Industries and Flowserve agreed to combine in an all-stock merger valued at ~$19B including debt, creating a differentiated leader in industrial process technologies.

Industrial companies Chart Industries Inc. and Flowserve Corp. agreed to merge in a deal valuing the combined company at about $19 billion.

Recursion Halts Four Pipeline Programs, Sharpening Cancer, Rare Disease Focus AI drug developer advances fourth Sanofi-partnered program, earns $7M milestone payment ...

Recursion Pharmaceuticals is expected to provide updates regarding the clinical-stage pipeline programs on its first-quarter earnings call. RXRX expects several data readouts throughout 2025.

Recursion to Present Preliminary Clinical Data from the Ongoing Phase 1b/2 trial of REC-4881 in FAP at Digestive Disease Week 2025 ...

In response to these policy shifts, Recursion announced today that its biotech accelerator Altitude Lab is launching a pre-seed venture fund to support biotech startups.

We recently published a list of the 10 Best Performing Healthcare Stocks So Far in 2025. In this article, we are going to take a look at where Recursion Pharmaceuticals, Inc.

Recursion and Exscientia, two pioneers in artificial intelligence (AI)-based drug development, have completed a business combination that they vowed will enhance their ability to carry out drug ...